Hutchmed (HCM) announced that the new drug application for the combination of Orpathys and Tagrisso has been granted approval by the China National Medical Products Administration for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR tyrosine kinase inhibitor therapy. This approval also triggers a $11M milestone payment from AstraZeneca (AZN), which markets both Orpathys and Tagrisso in China.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM: